Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer

详细信息    查看全文

• 作者：Glenn Liu ; M.D.^a ; ^{gxl@medicine.wisc.edu} ; Yu-Hui Chen ; M.S.^b ; Jill Kolesar ; Pharm. D.^a ; Wei Huang ; M.D.^a ; Robert DiPaola ; M.D.^c ; Michael Pins ; M.D.^d ; Michael Carducci ; M.D.^e ; Mark Stein ; M.D.^c ; Glenn J. Bubley ; M.D.^f ; George Wilding ; M.D.^a
• 关键词：Epidermal growth factor receptor ; Tyrosine kinase inhibitors ; Clinical trial
• 刊名：Urologic Oncology: Seminars and Original Investigations
• 出版年：2013
• 出版时间：February, 2013
• 年：2013
• 卷：31
• 期：2
• 页码：211-218
• 全文大小：588 K

文摘

Purpose

Activation of the epidermal growth factor pathway is important in prostate cancer development and the transcription of androgen receptor regulated genes. This study evaluated the potential activity of lapatinib in men with biochemically-relapsed androgen-dependent (stage D0) prostate cancer.

Patients and methods

Patients with a rising PSA after primary therapy for prostate cancer were enrolled. A PSA doubling time (PSADT) <12 months was required. Lapatinib was administered at 1,500 mg orally daily. Outcome measures were changes in PSA kinetics. Primary tumor blocks were obtained and assessed for EGFR expression, EGFR Q787Q polymorphism, and Kras 38 mutational status.

Results

Forty-nine patients were enrolled (14 ineligible), resulting in 35 patients for analysis. No PSA response was observed; best response was stable disease (n = 28, 80.0 % ). Pretreatment average slope was 0.19 log (PSA)/month (PSADT = 3.70 months), in contrast to on-treatment average slope of 0.13 log (PSA)/month (PSADT = 5.44 months) using linear mixed effects models (P = 0.006). Median progression-free survival (PFS) was 17.4 months for the high EGFR group and 6.0 months for the low EGFR group (P = 0.50). Patients with Kras 38 mutation had shorter PFS than those without Kras 38 mutation (P = 0.09).

Conclusion

Although no PSA responses (primary endpoint) was observed, lapatinib may have biologic activity in men with stage D0 prostate cancer as evidenced by a decrease in PSA slope in this non-randomized study. Additional trials assessing the role of EGFR overexpression and Kras wild type status in prostate cancer should be investigated.